MedTrace Logo

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

NCT06267092 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2026-01-08

No results posted yet for this study

Summary

Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. The study will last for about 6 months.

Part B: The study will look at how CagriSema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. The study will also look at how participants brain works when participants take the medicine. Participants will either get CagriSema or ''dummy'' medicine.

Conditions

Interventions

OTHER

No treatment given

Participants will not get any medicine during this study.

DRUG

Cagrilintide and Semaglutide

Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.

DRUG

Placebo

Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.

Sponsors & Collaborators

Principal Investigators

  • Clinical Reporting Office dept. 2834 · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2025-04-07
Completion
2025-12-08
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06267092 on ClinicalTrials.gov